Obstetric complications and clinical presentation in first episode of psychosis.


Journal

Acta neuropsychiatrica
ISSN: 1601-5215
Titre abrégé: Acta Neuropsychiatr
Pays: England
ID NLM: 9612501

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 26 5 2023
pubmed: 3 3 2023
entrez: 2 3 2023
Statut: ppublish

Résumé

Psychotic disorders exhibit a complex aetiology that combines genetic and environmental factors. Among the latter, obstetric complications (OCs) have been widely studied as risk factors, but it is not yet well understood how OCs relate to the heterogeneous presentations of psychotic disorders. We assessed the clinical phenotypes of individuals with a first episode of psychosis (FEP) in relation to the presence of OCs. Two-hundred seventy-seven patients with an FEP were assessed for OCs using the Lewis-Murray scale, with data stratified into three subscales depending on the timing and the characteristics of the obstetric event, namely: complications of pregnancy, abnormal foetal growth and development and difficulties in delivery. We also considered other two groups: any complications during the pregnancy period and all OCs taken altogether. Patients were clinically evaluated with the Positive and Negative Syndrome Scale for schizophrenia. Total OCs and difficulties in delivery were related to more severe psychopathology, and this remained significant after co-varying for age, sex, traumatic experiences, antipsychotic dosage and cannabis use. Our results highlight the relevance of OCs for the clinical presentation of psychosis. Describing the timing of the OCs is essential in understanding the heterogeneity of the clinical presentation.

Identifiants

pubmed: 36861430
pii: S0924270823000091
doi: 10.1017/neu.2023.9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

156-164

Auteurs

Norma Verdolini (N)

Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Gisela Mezquida (G)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Clinical Institute of Neuroscience, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain.

Isabel Valli (I)

Child and Adolescent Psychiatry and Psychology Department, Hospital Clinic of Barcelona, Institute of Neurosciences, CIBERSAM, IDIBAPS, University of Barcelona, Barcelona, Spain.

Clemente Garcia-Rizo (C)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Clinical Institute of Neuroscience, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain.

Manuel Cuesta (M)

Department of Psychiatry, Navarre Hospital Complex, IdiSNA, Navarre Institute for Health Research, Pamplona, Spain.

Eduard Vieta (E)

Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Miquel Bioque (M)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Clinical Institute of Neuroscience, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain.

Antonio Lobo (A)

Department of Medicine and Psychiatry, Universidad de Zaragoza; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza; CIBERSAM, Madrid, Spain.

Ana González-Pinto (A)

Hospital Universitario de Alava, Servicio de Psiquiatría, BIOARABA, CIBERSAM, University of the Basque Country, Spain.

Laura Pina-Camacho (L)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.

Iluminada Corripio (I)

Department of Psychiatry, CIBERSAM, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Marina Garriga (M)

Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

Inmaculada Baeza (I)

Child and Adolescent Psychiatry and Psychology Department, Hospital Clinic of Barcelona, Institute of Neurosciences, CIBERSAM, IDIBAPS, University of Barcelona, Barcelona, Spain.

Laura Martínez-Sadurní (L)

Hospital del Mar Medical Research Institute (IMIM), Autonomous University of Barcelona, CIBERSAM, Barcelona, Spain.

Byron Bitanihirwe (B)

The University of Manchester Humanitarian and Conflict Response Institute, UK.

Mary Cannon (M)

Department of Psychiatry, RCSI University of Medicine and Health Science, Dublin, Ireland.

Miquel Bernardo (M)

Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Clinical Institute of Neuroscience, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH